Reply: Proper monitoring instead of expanding treatment for improving the prognosis of indeterminate phase hepatitis B patients

Daniel Q Huang^{1

2}, Mindie H Nguyen^{3

4}

Affiliations

¹ Department of Medicine, Division of Gastroenterology and Hepatology, National University Hospital, Singapore.
² Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
³ Department of Medicine, Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, USA.
⁴ Department of Epidemiology and Population Health, Stanford University, Stanford, California, USA.

Comment

Daniel Q Huang et al. Hepatology. 2023.

. 2023 Nov 1;78(5):E95-E96.

doi: 10.1097/HEP.0000000000000525. Epub 2023 Jun 27.

Daniel Q Huang^{1

2}, Mindie H Nguyen^{3

4}

¹ Department of Medicine, Division of Gastroenterology and Hepatology, National University Hospital, Singapore.
² Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
³ Department of Medicine, Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, USA.
⁴ Department of Epidemiology and Population Health, Stanford University, Stanford, California, USA.

No abstract available

Comment on

Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase.
Huang DQ, Tran A, Yeh ML, Yasuda S, Tsai PC, Huang CF, Dai CY, Ogawa E, Ishigami M, Ito T, Kozuka R, Enomoto M, Suzuki T, Yoshimaru Y, Preda CM, Marin RI, Sandra I, Tran S, Quek SXZ, Khine HHTW, Itokawa N, Atsukawa M, Uojima H, Watanabe T, Takahashi H, Inoue K, Maeda M, Hoang JK, Trinh L, Barnett S, Cheung R, Lim SG, Trinh HN, Chuang WL, Tanaka Y, Toyoda H, Yu ML, Nguyen MH. Huang DQ, et al. Hepatology. 2023 Nov 1;78(5):1558-1568. doi: 10.1097/HEP.0000000000000459. Epub 2023 May 16. Hepatology. 2023. PMID: 37184202
Letter to the Editor: Proper monitoring instead of expanding treatment for improving the prognosis of indeterminate phase hepatitis B patients.
Jeng WJ, Liaw YF. Jeng WJ, et al. Hepatology. 2023 Nov 1;78(5):E93-E94. doi: 10.1097/HEP.0000000000000526. Epub 2023 Jun 27. Hepatology. 2023. PMID: 37369000 No abstract available.

1. Huang DQ, Tran A, Yeh ML, Yasuda S, Tsai PC, Huang CF, et al. Antiviral therapy substantially reduces hepatocellular carcinoma risk in chronic Hepatitis B patients in the indeterminate phase. Hepatology. 2023. doi: 10.1097/HEP.0000000000000459. - DOI
1. Huang DQ, Li X, Le MH, Le AK, Yeo YH, Trinh HN, et al. Natural history and hepatocellular carcinoma risk in untreated chronic hepatitis b patients with indeterminate phase. Clin Gastroenterol Hepatol. 2022;20:1803–1812.e1805.
1. Zhou K, Wahed AS, Cooper S, Di Bisceglie AM, Fontana RJ, Ghany MG, et al. Phase transition is infrequent among north american adults with e-antigen-negative chronic hepatitis B and low-level viremia. Am J Gastroenterol. 2019;114:1753–1763.
1. Oliveri F, Surace L, Cavallone D, Colombatto P, Ricco G, Salvati N, et al. Long-term outcome of inactive and active, low viraemic HBeAg-negative-hepatitis B virus infection: Benign course towards HBsAg clearance. Liver International. 2017;37:1622–1631.
1. Lok AS, Perrillo R, Lalama CM, Fried MW, Belle SH, Ghany MG, et al. Low incidence of adverse outcomes in adults with chronic hepatitis B virus infection in the era of antiviral therapy. Hepatology. 2021;73:2124–2140.